NIH grant aims to locate high-frequency oscillations to reduce pediatric seizures
Developed by CHOC and UC Irvine, a new way to control pediatric seizures uses densely spaced electrodes to map high-frequency oscillations.
New tool for craniosynostosis treatment highlights Neuroscience Institute’s push to advance care
A recently installed 3D camera system in CHOC's neurosurgery clinic will significantly advance CHOC's mission to treat craniosynostosis.
LITT: Prolonging life, limiting complications in recurrent medulloblastoma
A year after undergoing laser interstitial thermal therapy, a young patient showed significant reduction in tumor size and enhancement.
Virtual pediatric lecture series: Macrocephaly and Hydrocephalus
CHOC’s virtual pediatric lecture series continues with a lesson on macrocephaly and hydrocephalus. This online discussion will be held Aug. 25.
CHOC intraventricular hemorrhage and hydrocephalus patient accepted to medical school
Twenty-four years ago, Dr. Michael Muhonen, treated a baby born with what essentially was a traumatic brain injury. That baby, Eric Rhee, is now 24 and headed off to medical school.
Boy, 9, showing great progress after deep brain stimulation procedure at CHOC
Ryder Montano is the third and youngest CHOC patient with a movement disorder to undergo a procedure called deep brain stimulation (DBS).
Neuroscience leaders discuss innovations and their successes, and the need for much more work to be done
CHOC’s leading pediatric neurosurgeons recently shared their insights on how innovation is helping to close the gap between clinical needs and the availability of pediatric devices.
Three-stage DBS results in better outcomes for secondary dystonia
Due to the complexity of secondary dystonia and the brain’s potentially unpredictable response, deep brain stimulation (DBS) has seldom been used in the treatment of this disorder. However, a CHOC neuroscientist has developed a breakthrough method of DBS to treat secondary dystonia in pediatric patients.
CHOC awarded $2.3-million grant to study how toxic stress and unpredictability in the early environment affects neurodevelopment
The state of California has awarded CHOC, in partnership with UC Irvine and Chapman University, a $2.3-million grant to screen patients for adverse childhood experiences (ACEs) and childhood unpredictability to assess how such high-stress events affect the brain and put kids at increased risk of later developing physical and mental illnesses.
Batten disease patients highlight CHOC’s growing reputation as a destination for kids with rare conditions
There is no cure for CLN2 disease. But thanks to genetic scientists, neurosurgeons and nurses at CHOC, there is hope for delaying progression of the disease. The therapy, Brineura, is a medication that treats the brain via a port under the scalp with a synthetic form of the missing enzyme. CLN2 patients come to CHOC every two weeks for the four-hour infusion to keep the drug working effectively.